CN1184320C - Mhc-ⅱ类配体作为疫苗佐剂以及lag-3用于癌症治疗的应用 - Google Patents
Mhc-ⅱ类配体作为疫苗佐剂以及lag-3用于癌症治疗的应用 Download PDFInfo
- Publication number
- CN1184320C CN1184320C CNB988075474A CN98807547A CN1184320C CN 1184320 C CN1184320 C CN 1184320C CN B988075474 A CNB988075474 A CN B988075474A CN 98807547 A CN98807547 A CN 98807547A CN 1184320 C CN1184320 C CN 1184320C
- Authority
- CN
- China
- Prior art keywords
- lag
- mhc
- cell
- antigen
- tumour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000017578 LAG3 Human genes 0.000 title claims abstract 19
- 101150030213 Lag3 gene Proteins 0.000 title claims abstract 19
- 206010028980 Neoplasm Diseases 0.000 title claims description 92
- 201000011510 cancer Diseases 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title claims description 10
- 102000043131 MHC class II family Human genes 0.000 title abstract 4
- 108091054438 MHC class II family Proteins 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title abstract 4
- 238000002255 vaccination Methods 0.000 title description 7
- 239000002671 adjuvant Substances 0.000 title description 3
- 239000000427 antigen Substances 0.000 claims abstract description 39
- 102000036639 antigens Human genes 0.000 claims abstract description 39
- 108091007433 antigens Proteins 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 15
- 230000028993 immune response Effects 0.000 claims abstract description 12
- 230000001575 pathological effect Effects 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 99
- 210000004881 tumor cell Anatomy 0.000 claims description 54
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 17
- 238000001890 transfection Methods 0.000 claims description 13
- 230000001404 mediated effect Effects 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 230000000890 antigenic effect Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 230000007969 cellular immunity Effects 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 238000002619 cancer immunotherapy Methods 0.000 abstract description 2
- 230000000145 adjuvantlike effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 49
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 42
- 230000000694 effects Effects 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012646 vaccine adjuvant Substances 0.000 description 4
- 229940124931 vaccine adjuvant Drugs 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- -1 B7.2 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 2
- 230000037111 immune power Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- KVFJBIQWENJTDM-UHFFFAOYSA-N 1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CCC1=CC=C3)=C1C3=C2 KVFJBIQWENJTDM-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 101150075764 CD4 gene Proteins 0.000 description 1
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101001137986 Mus musculus Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000804765 Mus musculus Lymphotactin Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
病原体 | 因子 | 疾病 |
病毒 | HIVHBV,HCVHSV,CMV,HHVHTLV1 | AIDS肝炎移植失败,Kaposi肉瘤癌症 |
胞内细菌 | 李斯特杆菌分支杆菌 | 李斯特杆菌病麻风病、结核病 |
胞内寄生虫 | 疟原虫属等 | 疟疾 |
癌基因等 | 大多数癌、黑色素瘤、白血病 |
Claims (22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97401800A EP0893507A1 (en) | 1997-07-25 | 1997-07-25 | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
EP97401800.4 | 1997-07-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1265149A CN1265149A (zh) | 2000-08-30 |
CN1184320C true CN1184320C (zh) | 2005-01-12 |
Family
ID=8229825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988075474A Expired - Lifetime CN1184320C (zh) | 1997-07-25 | 1998-07-23 | Mhc-ⅱ类配体作为疫苗佐剂以及lag-3用于癌症治疗的应用 |
Country Status (20)
Country | Link |
---|---|
US (2) | US6410509B1 (zh) |
EP (3) | EP0893507A1 (zh) |
JP (1) | JP4723722B2 (zh) |
KR (1) | KR100603075B1 (zh) |
CN (1) | CN1184320C (zh) |
AT (2) | ATE324455T1 (zh) |
AU (1) | AU753738B2 (zh) |
BR (1) | BR9811037A (zh) |
CA (2) | CA2732570C (zh) |
DE (2) | DE69834330T2 (zh) |
DK (1) | DK1002108T3 (zh) |
EA (3) | EA005405B1 (zh) |
EE (1) | EE200000039A (zh) |
ES (1) | ES2262242T3 (zh) |
HK (1) | HK1030014A1 (zh) |
IL (2) | IL134212A0 (zh) |
NO (1) | NO20000378L (zh) |
PT (1) | PT1002108E (zh) |
UA (1) | UA75322C2 (zh) |
WO (1) | WO1999004810A2 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1295895B1 (en) * | 2001-09-19 | 2011-08-10 | Institut Gustave Roussy | Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof |
SI1897548T1 (sl) | 2003-02-28 | 2013-12-31 | The Johns Hopkins University | Regulacija celic T |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
FR2868781B1 (fr) * | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
WO2011031139A1 (en) | 2009-09-09 | 2011-03-17 | Universiteit Utrecht Holding B.V. | An ataq protein or a part thereof as a vaccine |
SA110310855B1 (ar) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
SG190222A1 (en) | 2010-11-10 | 2013-06-28 | Leti Sl Lab | New adjuvant |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN103751778B (zh) * | 2014-01-28 | 2016-09-28 | 复旦大学 | 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用 |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
CA3116265A1 (en) | 2014-10-07 | 2016-04-14 | Cytlimic Inc. | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell |
WO2016094639A1 (en) * | 2014-12-10 | 2016-06-16 | Wisconsin Alumni Research Foundation | Mini-intronic plasmid dna vaccines in combination with lag3 blockade |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
DK3269733T3 (da) | 2015-03-09 | 2020-07-27 | Cytlimic Inc | Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler |
ES2844049T3 (es) | 2015-04-07 | 2021-07-21 | Cytlimic Inc | Adyuvante para vacunas contra el cáncer |
MA42420A (fr) | 2015-05-13 | 2018-05-23 | Agenus Inc | Vaccins pour le traitement et la prévention du cancer |
EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
US10265379B2 (en) | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
US20180256633A1 (en) | 2015-09-18 | 2018-09-13 | Rijksuniversiteit Groningen | Long chain inulin for stimulating an immune response |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
WO2019210055A2 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
CA3114585A1 (en) * | 2018-09-27 | 2020-04-02 | Genocea Biosciences, Inc. | Treatment methods |
JP2020138940A (ja) | 2019-02-28 | 2020-09-03 | テルモ株式会社 | 治療方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT88641B (pt) * | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
AU647013B2 (en) * | 1988-08-22 | 1994-03-17 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Retroviral vectors expressing soluble CD4: a gene therapy for aids |
JPH02231083A (ja) * | 1988-08-31 | 1990-09-13 | Eisai Co Ltd | 組換ナチュラルキラー細胞活性化因子 |
EP0385909B1 (en) * | 1989-03-03 | 1994-07-13 | MicroGeneSys, Inc. | A kit or composition for the prevention or treatment of HIV-1 infections |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
AU675702B2 (en) * | 1993-01-26 | 1997-02-13 | Leslie R. Coney | Compositions and methods for delivery of genetic material |
SE510135C2 (sv) * | 1994-05-05 | 1999-04-19 | Berol Nobel Ab | Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition |
ATE352617T1 (de) * | 1994-05-06 | 2007-02-15 | Roussy Inst Gustave | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper |
MX9700560A (es) * | 1994-08-05 | 1997-05-31 | Warner Lambert Co | Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales. |
CA2206471A1 (en) * | 1994-12-07 | 1996-06-13 | Hoffmann-La Roche Inc. | Monoclonal antibody fragments having immunosuppressant activity |
EP0800534A2 (en) * | 1994-12-23 | 1997-10-15 | Laboratoires Om S.A. | Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases |
AU1355697A (en) * | 1995-12-28 | 1997-07-28 | Johns Hopkins University School Of Medicine, The | Allogeneic paracrine cytokine tumor vaccines |
-
1997
- 1997-07-25 EP EP97401800A patent/EP0893507A1/en not_active Withdrawn
-
1998
- 1998-07-23 AU AU92547/98A patent/AU753738B2/en not_active Expired
- 1998-07-23 EP EP98945090A patent/EP1002108B1/en not_active Expired - Lifetime
- 1998-07-23 ES ES98945090T patent/ES2262242T3/es not_active Expired - Lifetime
- 1998-07-23 KR KR1020007000265A patent/KR100603075B1/ko not_active IP Right Cessation
- 1998-07-23 DK DK98945090T patent/DK1002108T3/da active
- 1998-07-23 JP JP2000503862A patent/JP4723722B2/ja not_active Expired - Lifetime
- 1998-07-23 AT AT98945090T patent/ATE324455T1/de active
- 1998-07-23 PT PT98945090T patent/PT1002108E/pt unknown
- 1998-07-23 EA EA200200565A patent/EA005405B1/ru not_active IP Right Cessation
- 1998-07-23 UA UA2000020976A patent/UA75322C2/uk unknown
- 1998-07-23 CN CNB988075474A patent/CN1184320C/zh not_active Expired - Lifetime
- 1998-07-23 BR BR9811037-3A patent/BR9811037A/pt not_active IP Right Cessation
- 1998-07-23 EE EEP200000039A patent/EE200000039A/xx unknown
- 1998-07-23 AT AT06008545T patent/ATE478956T1/de not_active IP Right Cessation
- 1998-07-23 DE DE69834330T patent/DE69834330T2/de not_active Expired - Lifetime
- 1998-07-23 EA EA200300092A patent/EA200300092A1/ru unknown
- 1998-07-23 DE DE69841866T patent/DE69841866D1/de not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004621 patent/WO1999004810A2/en active IP Right Grant
- 1998-07-23 EA EA200000161A patent/EA003740B1/ru not_active IP Right Cessation
- 1998-07-23 IL IL13421298A patent/IL134212A0/xx unknown
- 1998-07-23 CA CA2732570A patent/CA2732570C/en not_active Expired - Lifetime
- 1998-07-23 CA CA2293805A patent/CA2293805C/en not_active Expired - Lifetime
- 1998-07-23 EP EP06008545A patent/EP1698701B1/en not_active Expired - Lifetime
-
2000
- 2000-01-24 IL IL134212A patent/IL134212A/en not_active IP Right Cessation
- 2000-01-25 NO NO20000378A patent/NO20000378L/no not_active Application Discontinuation
- 2000-01-27 US US09/492,113 patent/US6410509B1/en not_active Expired - Lifetime
-
2001
- 2001-01-30 HK HK01100662A patent/HK1030014A1/xx not_active IP Right Cessation
-
2002
- 2002-01-10 US US10/041,600 patent/US7109026B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1184320C (zh) | Mhc-ⅱ类配体作为疫苗佐剂以及lag-3用于癌症治疗的应用 | |
CN1805758A (zh) | 核酸和细胞疫苗的组分 | |
CN1646155A (zh) | 癌症疗法 | |
AU704012B2 (en) | Gene therapy for effector cell regulation | |
CN1515319A (zh) | 细胞毒t淋巴细胞应答的诱导 | |
CN1650015A (zh) | 编码cea和cd40配体的dna疫苗及其使用方法 | |
US20070298051A1 (en) | Adjuvants Of Immune Response | |
CN1434718A (zh) | 免疫系统的激活和抑制 | |
CN1705739A (zh) | 用作抗原递送系统的抗原转导的t细胞 | |
CN1646153A (zh) | 抗血管生成的主动免疫疗法 | |
CN1194000A (zh) | 增强保护性免疫应答的方法 | |
CN1168740C (zh) | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 | |
CN1858059A (zh) | 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途 | |
JP2975117B2 (ja) | 腫瘍疾患の治療のための生ワクチン | |
CN101080420A (zh) | 胸腺特异性蛋白质 | |
CN1377279A (zh) | 可溶性共同刺激分子增强免疫应答的用途 | |
EP2042191B1 (en) | Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination | |
CN1948333A (zh) | 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用 | |
Bianchi et al. | Idiotypic vaccination in B-cell malignancies | |
Bonnekoh et al. | Immunological gene therapy approaches for malignant melanoma: 2. Preclinical Studies and Clinical Strategies | |
CN1887296A (zh) | 一种诱导抗肿瘤免疫的方法及其在制药中的应用 | |
CA2253790C (en) | Methods of enhancing anti-tumour immunity in a mammal | |
CN1753994A (zh) | 疫苗 | |
CN1372474A (zh) | 用于预防或减轻病理性血管发生状况的方法 | |
US20230321222A1 (en) | Immune Adjuvant Comprising Hepatitis B Virus-Derived Polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MERCK SERONO S. A. Free format text: FORMER OWNER: SERONO LAB Effective date: 20120116 Owner name: SERONO LAB Free format text: FORMER OWNER: APPLIED RESEARCH SYSTEMS ARS HOLDING N. V. Effective date: 20120116 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120116 Address after: Villejuif, France Co-patentee after: Merck Serono S.A. Patentee after: Gustav Roussi Institute Address before: Villejuif, France Co-patentee before: LABORATOIRES SERONO S.A. Patentee before: Gustav Roussi Institute Effective date of registration: 20120116 Address after: Villejuif, France Co-patentee after: LABORATOIRES SERONO S.A. Patentee after: Gustav Roussi Institute Address before: Villejuif, France Co-patentee before: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. Patentee before: Gustav Roussi Institute |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20000830 Assignee: Eddingpharm Investment Co.,Ltd. Assignor: Immutep Contract record no.: 2015990000162 Denomination of invention: Use of class MHC-11 ligands as vaccine adjuvants and LAG-3 for cancer therapy Granted publication date: 20050112 License type: Exclusive License Record date: 20150402 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CX01 | Expiry of patent term |
Granted publication date: 20050112 |
|
CX01 | Expiry of patent term |